These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 12765334)

  • 21. Serotonin-dopamine interaction and its relevance to schizophrenia.
    Kapur S; Remington G
    Am J Psychiatry; 1996 Apr; 153(4):466-76. PubMed ID: 8599393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of serotonin in the action of atypical antipsychotic drugs.
    Meltzer HY
    Clin Neurosci; 1995; 3(2):64-75. PubMed ID: 7583621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Dopamine D4-receptor variants, schizophrenia and clozapine therapy].
    Ewald HL; Mors NP; Rosenberg R
    Ugeskr Laeger; 1996 Jun; 158(25):3601-3. PubMed ID: 8693618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Biochemistry of schizophrenia and mechanism of action of neuroleptics].
    Loo H; Cuche H; Sechter D
    Sem Hop; 1982 Dec; 58(44):2565-72. PubMed ID: 6130604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Atypical pharmacologic characteristics of an antipsychotic drug: clozapine].
    Gosselin O; Ribeyre JM; Kahn JP
    Encephale; 1997 Sep; 23 Spec No 4():2-6. PubMed ID: 9417400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anabasine, a selective nicotinic acetylcholine receptor agonist, antagonizes MK-801-elicited mouse popping behavior, an animal model of schizophrenia.
    Mastropaolo J; Rosse RB; Deutsch SI
    Behav Brain Res; 2004 Aug; 153(2):419-22. PubMed ID: 15265637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New drugs for schizophrenia: an update for family physicians.
    Amadio PB; Cross LB; Amadio P
    Am Fam Physician; 1997 Sep; 56(4):1149-56, 1159-60. PubMed ID: 9310066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PDE Inhibitors for the Treatment of Schizophrenia.
    Snyder GL; Vanover KE
    Adv Neurobiol; 2017; 17():385-409. PubMed ID: 28956340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New perspectives on biological treatment of schizophrenia.
    Lingjaerde O
    Acta Psychiatr Scand Suppl; 1994; 384():102-7. PubMed ID: 7879631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients.
    Javitt DC
    Curr Opin Psychiatry; 2006 Mar; 19(2):151-7. PubMed ID: 16612195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alpha7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia.
    Bencherif M; Stachowiak MK; Kucinski AJ; Lippiello PM
    Med Hypotheses; 2012 May; 78(5):594-600. PubMed ID: 22336089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic.
    Ereshefsky L
    J Clin Psychiatry; 1999; 60 Suppl 10():20-30. PubMed ID: 10340684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Towards more effective antipsychotic treatment.
    Kane JM; Freeman HL
    Br J Psychiatry Suppl; 1994 Nov; (25):22-31. PubMed ID: 7865194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update.
    Chaves C; Marque CR; Trzesniak C; Machado de Sousa JP; Zuardi AW; Crippa JA; Dursun SM; Hallak JE
    Braz J Med Biol Res; 2009 Nov; 42(11):1002-14. PubMed ID: 19855900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biological perspectives: the role of glutamate in schizophrenia and its treatment.
    Steele D; Moore RL; Swan NA; Grant JS; Keltner NL
    Perspect Psychiatr Care; 2012 Jul; 48(3):125-8. PubMed ID: 22724397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia.
    Haleem DJ
    J Coll Physicians Surg Pak; 2006 Aug; 16(8):556-62. PubMed ID: 16899192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New insights into the biology of schizophrenia through the mechanism of action of clozapine.
    Brunello N; Masotto C; Steardo L; Markstein R; Racagni G
    Neuropsychopharmacology; 1995 Nov; 13(3):177-213. PubMed ID: 8602893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.
    Miyamoto S; Duncan GE; Marx CE; Lieberman JA
    Mol Psychiatry; 2005 Jan; 10(1):79-104. PubMed ID: 15289815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of the simultaneous enhancement of NMDA and dopamine D1 receptor-mediated neurotransmission in the effects of clozapine on phencyclidine-induced acute increases in glutamate levels in the rat medial prefrontal cortex.
    Abekawa T; Ito K; Koyama T
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Dec; 374(3):177-93. PubMed ID: 17103144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.